Rheumatoid Arthritis Clinical Trial
— MuTregOfficial title:
n Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases
Interleukin 2 (IL-2) is a critical cytokine for the survival and function of regulatory T cells (LTreg). This cytokine has a dual role in the immune system. IL-2 stimulates immune responses by acting on the intermediate affinity IL-2R receptor, IL-2Rβγ, expressed by conventional T cells (LTconv) during activation, but also contributes to the inhibition of immune responses via LTreg that express the high affinity receptor IL-2Rαβγ. This difference in IL-2 receptor affinity for IL-2 has led to the development of low-dose IL-2 therapy to stimulate LTreg and improve control of excessive inflammation in autoimmune (AID), inflammatory or alloimmune diseases Low-dose IL-2 therapy is being studied in several of these diseases such as systemic lupus erythematosus, type 1 diabetes, alopecia, HCV (hepatitis C virus)-induced vasculitis, atopic dermatitis and chronic allo-transplantation-related graft-versus-host disease (GVHD). Some of these studies have shown an increase in LTreg numbers and an improvement in certain clinical signs. To improve LTreg targeting in autoimmune diseases, inflammatory diseases or GVHD, mutated IL-2s (muteins) have been developed with selective LTreg agonist properties. These IL-2 muteins are linked to an Fc fragment to increase their half-life. Two IL-2 variants (IL-2Vs)-Fc preferentially stimulate STAT5 phosphorylation in LTregs compared to conventional FoxP3- (LTconv) CD4+ or CD8+ T cells
Status | Not yet recruiting |
Enrollment | 90 |
Est. completion date | April 15, 2023 |
Est. primary completion date | April 15, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Inclusion criteria common to all patients in different departments: - Age18 years - Affiliated to social security or entitled to - Patient who has been informed of the study and has signed a free and informed consent Inclusion criteria specific by department: Inclusion criteria for Clinical Hematology Department: - Patient with GVHD following allogeneic hematopoietic stem cell transplantation (HSC) - Or with acquired bone marrow suppression - Lymphocytosis > 0.5 G/L Inclusion criteria for Nephrology and Transplantation department: - Patient with systemic lupus erythematosus (ACR classification criteria) Inclusion criteria for Neurology department: - Patient with multiple sclerosis (criteria of Mc Donald 2017) Inclusion criteria for Rheumatology Department: - Patient with rheumatoid arthritis (ACR classification criteria) Inclusion criteria for Internal Medicine-Endocrinology Department: - Patient with Basedow disease, Hashimoto's thyroiditis Inclusion criteria for Dermatology Department: - Patient with vitiligo or alopecia areata or atopic dermatitis Exclusion Criteria: Non-inclusion criteria common to all patients: - Patient under guardianship, curatorship or judicial protection - Pregnant, parturient or breastfeeding woman - Patient deprived of liberty - Patient hospitalized without consent - Patient admitted to a health or social institution for purposes other than research - Minor patient - Adult patient unable to express consent - Refusal to participate - Patient on AME Non-inclusion criteria specific by department: Non-inclusion criteria for Clinical Hematology Department: - Ongoing treatment with high doses (>1 mg/kg/d) of systemic corticosteroid therapy - Ongoing treatment with JAK inhibitors Non-inclusion criteria for Nephrology and Transplantation Department: - Ongoing treatment with doses >10 mg/d Prednisone - Ongoing treatment with Cellcept, Endoxan, Imurel, Belimumab, Anti-CD20, Methotrexate - Ongoing treatment with JAK inhibitors Non-inclusion criteria for Neurology Department: - Treatment with systemic corticosteroid therapy, Fingolimod or Teriflunomide - Ongoing treatment with JAK inhibitors - Lymphocytosis < 0.5 G/L Non-inclusion criteria for Rheumatology Department: - Ongoing treatment with doses >15 mg/d Prednisone - Treatment with Rituximab or Tocilizumab - Ongoing treatment with JAK inhibitors - Lymphocytosis < 0.5 G/L Non-inclusion criteria for Internal Medicine - Endocrinology Department: - Ongoing immunosuppressive therapy - Ongoing treatment with JAK inhibitors Non-inclusion criteria for Dermatology Department: - Ongoing treatment with Methotrexate - Ongoing treatment with JAK inhibitors - Ongoing treatment with doses >10 mg/d prednisone |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the percentage of phosphorylated STAT5 in LTresg compared to LTconv after incubation with IL-2 muteins | The measurement method is based on the quantification of the phosphorylated STAT5 molecule in LTconv and LTreg by flow cytometry after incubating the cells with IL-2 or IL-2 muteins | At inclusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |